Zobrazeno 1 - 10
of 101
pro vyhledávání: '"Truman J, Milling"'
Autor:
Gregory J. Fermann, Brooks D. Cash, Nayantara Coelho‐Prabhu, Marc Maegele, Roland Bingisser, Vinay Sehgal, Alexander T. Cohen, Anna Hundt Golden, Jon Russo, Mark Price, Allen Mangel, Bruce Koch, Mary J. Christoph, Truman J. Milling Jr.
Publikováno v:
Journal of the American College of Emergency Physicians Open, Vol 4, Iss 5, Pp n/a-n/a (2023)
Abstract Objective To define and contextualize life‐threatening gastrointestinal (GI) bleeding in the setting of factor Xa (FXa) inhibitor therapy and to derive a consensus‐based, clinically oriented approach to the administration of FXa inhibito
Externí odkaz:
https://doaj.org/article/1270a691872e4c78bfdff0c178ab6aa6
Autor:
Adrienne N. Dula, Truman J. Milling, S. Claiborne Johnston, Jayson Aydelotte, Gary W. Peil, Alec Robinson, Kaiz Asif, Stephen Pan, Sohan Parekh, Steven Warach
Publikováno v:
Trials, Vol 24, Iss 1, Pp 1-7 (2023)
Abstract Background Imaging repositories are commonly attached to ongoing clinical trials, but capturing, transmitting, and storing images can be complicated and labor-intensive. Typical methods include outdated technologies such as compact discs. El
Externí odkaz:
https://doaj.org/article/e554855269194bc78a0ce8aba9410b30
Autor:
Majed A. Refaai MD, Paolo Bajcic MD, Robert McNeill PharmD, MBA, Christopher Hood PharmD, MBA, Truman J. Milling MD
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis, Vol 29 (2023)
Real-world utilization of 4-factor prothrombin complex concentrate (4F-PCC) and plasma for the management of oral anticoagulant (OAC)-associated bleeding in US trauma hospitals was described. This is amulticenter, retrospective chart review evaluatin
Externí odkaz:
https://doaj.org/article/7bad0e4d36b94d94b7b60093c8dfc42d
Autor:
Grant C. O’Connell, Kyle B. Walsh, Christine G. Smothers, Suebsarn Ruksakulpiwat, Bethany L. Armentrout, Chris Winkelman, Truman J. Milling, Steven J. Warach, Taura L. Barr
Publikováno v:
BMC Neurology, Vol 22, Iss 1, Pp 1-13 (2022)
Abstract Background The development of tools that could help emergency department clinicians recognize stroke during triage could reduce treatment delays and improve patient outcomes. Growing evidence suggests that stroke is associated with several c
Externí odkaz:
https://doaj.org/article/310a178bda384b22bf7c3a447a591363
Autor:
Christopher Hood, Joshua N. Goldstein, Truman J. Milling, Majed A. Refaai, Paolo Bajcic, Brahm Goldstein, Ravi Sarode
Publikováno v:
Blood Advances. 7:2206-2213
Restoration of the international normalized ratio (INR) to values
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a71b9dccbff38ef6ce773be07602b42
https://doi.org/10.1182/bloodadvances.2022009015
https://doi.org/10.1182/bloodadvances.2022009015
Autor:
Cesar Astudillo, Christy Ankrom, Alyssa Trevino, Rene M Malazarte, Arvind B Bambhroliya, Christopher H Topel, Truman J Milling, Tzu-Ching Wu
Publikováno v:
BMJ Open, Vol 9, Iss 9 (2019)
Introduction The Lone Star Stroke Consortium Telestroke Registry (LeSteR) currently consisting of 3 academic hub centres and 27 partner spokes is a statewide initiative organised by leading academic health centres in the State of Texas to understand
Externí odkaz:
https://doaj.org/article/1c92dfab6dff45428afff6ee224fc6a0
Autor:
Truman J Milling
Publikováno v:
Thrombosis and Haemostasis.
No Abstract
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::63eb1b5f081b5c4f0bc23d3bff82546d
https://doi.org/10.1055/a-2097-0775
https://doi.org/10.1055/a-2097-0775
Autor:
Alexander P, Benz, Lizhen, Xu, John W, Eikelboom, Saskia, Middeldorp, Truman J, Milling, Mark, Crowther, Patrick, Yue, Pamela, Conley, Genmin, Lu, Stuart J, Connolly
Publikováno v:
Thrombosis and Haemostasis, 122, 998-1005
Thrombosis and Haemostasis, 122, 6, pp. 998-1005
Thrombosis and haemostasis, 122(6), 998-1005. Schattauer GmbH
Thrombosis and Haemostasis, 122, 6, pp. 998-1005
Thrombosis and haemostasis, 122(6), 998-1005. Schattauer GmbH
Background Andexanet alfa (andexanet) is approved for specific anticoagulation reversal in patients with life-threatening or uncontrolled bleeding during treatment with rivaroxaban or apixaban. There is limited experience with andexanet in patients w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b62a6eac18ed9bc2d57aeaf5c5f0b05
https://hdl.handle.net/2066/282358
https://hdl.handle.net/2066/282358
Autor:
Truman J. Milling, Saskia Middeldorp, Lizhen Xu, Bruce Koch, Andrew Demchuk, John W. Eikelboom, Peter Verhamme, Alexander T. Cohen, Jan Beyer-Westendorf, C. Michael Gibson, Jose Lopez-Sendon, Mark Crowther, Ashkan Shoamanesh, Michiel Coppens, Jeannot Schmidt, Pierre Albaladejo, Stuart J. Connolly, R. Anand, A. Bastani, C. Clark, M. Concha, J. Cornell, K. Dombrowski, G. Fermann, J. Fulmer, J. Goldstein, D. Kereiakes, T. Milling, D. Pallin, N. Patel, M. Refaai, M. Rehman, A. Schmaier, E. Schwarz, W. Shillinglaw, M. Spohn, T. Takata, A. Venkat, J. Welker, I. Welsby, J. Wilson, L. Van Keer, F. Verschuren, M. Blostein, J. Eikelboom, K. Althaus, J. Berrouschot, G. Braun, T. Doeppner, R. Dziewas, S. Genth-Zotz, P. Greinacher, F. Hamann, F. Hanses, W. Heide, B. Kallmuenzer, P. Kermer, S. Poli, G. Royl, S. Schellong, S. Schnupp, J. Schwarze, C. Spies, G. Thomalla, M. von Mering, K. Weissenborn, F. Wollenweber, C. Gumbinger, U. Jaschinski, M. Maschke, H-C. Mochmann, W. Pfeilschifter, C. Pohlmann, R. Zahn, P. Bouzat, J. Schmidt, C. Vallejo, B. Floccard, M. Coppens, S. van Wissen, E. Arellano-Rodrigo, E. Valles, R. Alikhan, K. Breen, R. Hall, M. Crowther, P. Albaladejo, A. Cohen, A.M. Demchuk, D.G. Wyse, D.A. Garcia, M. Prins, J. Nakamya, H.R. Büller, K. W. Mahaffey, J. H. Alexander, J.A. Cairns, R.G. Hart, C.D. Joyner, G.E. Raskob, S. Schulman, R. Veltkamp, B. Meeks, E. Zotova, S. Ahmad, T. Pinto, K. Baker, A. Dykstra, I. Holadyk-Gris, A. Malvaso
Publikováno v:
Circulation, 147(13), 1026-1038. Lippincott Williams and Wilkins
Circulation, 147, 1026-1038
Circulation, 147, 13, pp. 1026-1038
Circulation, 147, 1026-1038
Circulation, 147, 13, pp. 1026-1038
Background: Andexanet alfa is a modified recombinant inactive factor Xa (FXa) designed to reverse FXa inhibitors. ANNEXA-4 (Andexanet Alfa, a Novel Antidote to the Anticoagulation Effects of Factor Xa Inhibitors) was a multicenter, prospective, phase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::695a7e25001773b8815804ca94e1485d
https://pure.amc.nl/en/publications/final-study-report-of-andexanet-alfa-for-major-bleeding-with-factor-xa-inhibitors(4e567d40-6ad1-4f6b-9b9a-efacc6ca3b22).html
https://pure.amc.nl/en/publications/final-study-report-of-andexanet-alfa-for-major-bleeding-with-factor-xa-inhibitors(4e567d40-6ad1-4f6b-9b9a-efacc6ca3b22).html
Autor:
Simin Roward, Jo Wick, Todd W. Costantini, Truman J. Milling, Gregory Y.H. Lip, Dinesh Pal Mudaranthakam, Alexander Muddiman, Ben King, Adrienne N. Dula, Byron J. Gajewski, S. Claiborne Johnston, Steven Warach, Michelle A. Price
Publikováno v:
J Neurotrauma
Anticoagulants prevent thrombosis and death in patients with atrial fibrillation and venous thromboembolism (VTE) but also increase bleeding risk. The benefit/risk ratio favors anticoagulation in most of these patients. However, some will have a blee
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f745bd0e466c5027839e7997bb7f81af
https://doi.org/10.1089/neu.2020.7535
https://doi.org/10.1089/neu.2020.7535